Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
ID: 332068Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Nonprofits Without 501(c)(3) Status

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/332068

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-123.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" aimed at the development and validation of animal models and ex vivo systems to enhance neurotherapeutic discovery. This initiative seeks applications that focus on creating validated models demonstrating significant improvements over existing systems, thereby increasing the translational relevance for treating neurological or neuromuscular disorders. The funding is structured in a phased approach (R61/R33), emphasizing internal validation in the R61 phase and external validation in the R33 phase, with a requirement for clear milestones and collaboration among multidisciplinary teams. Interested applicants must adhere to NIH guidelines and submit proposals by October 21, 2024, with no cost-sharing or matching requirements. For further information, contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement page at http://grants.nih.gov/grants/guide/pa-files/PAR-21-123.html.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-21-123-Full-Announcement.html
    PAR-21-123.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity titled Innovation Grants to Nurture Initial Translational Efforts (IGNITE), specifically aimed at the development and validation of animal models and ex vivo systems for neurotherapeutic discovery. This initiative invites applications focused on creating validated models that demonstrate significant improvements over existing systems, thereby enhancing the translational relevance in the treatment of neurological or neuromuscular disorders. The funding is intended for projects utilizing a phased approach (R61/R33), with an emphasis on internal validation in the R61 phase and external validation in the R33 phase. Applicants must provide clear milestones for progression between phases and demonstrate collaboration among multidisciplinary teams. The initiative encourages diversity in applicant teams and outlines eligibility for various organizations. Submissions must adhere to stringent NIH guidelines, including required registrations and a defined research strategy addressing the proposed model's feasibility, validity, and relevance to drug discovery. The overall goal is to facilitate advancements in therapeutic efficacy through improved models that predict clinical outcomes.
    Similar Opportunities
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) funding opportunity, aimed at supporting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies of therapeutic agents for neurological and neuromuscular disorders. This grant follows the R61/R33 phased award mechanism, where the R61 phase focuses on preparation and characterization, while the R33 phase emphasizes efficacy studies, with a critical transition contingent upon meeting specific milestones. The program encourages collaboration among various organizations, including nonprofit entities and academic institutions, to accelerate the development of promising therapies, with awards capped at $750,000 over a maximum project duration of three years. Interested applicants can find more information and application instructions at the NIH grants website, and the deadline for submissions is October 20, 2027.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Innovation Grants to Nurture Initial Translational Efforts (IGNITE) aimed at developing assays and identifying therapeutic agents for neurological and neuromuscular disorders. This funding opportunity encourages research grant applications focused on assay development and iterative screening to characterize potential therapeutics, operating under the R61/R33 phased award mechanism that requires progression based on achieving specific milestones. The initiative is crucial for advancing scientific knowledge and addressing significant health challenges, with a total estimated program funding of $750,000 and an award ceiling of $750,000. Applications are due starting January 18, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This funding opportunity supports projects through two phases: R61 for non-clinical activities and R33 for small clinical studies, with a focus on ensuring compliance with Environmental Health and Safety regulations. The program emphasizes diversity in applicant teams and requires a Plan for Enhancing Diverse Perspectives, with key deadlines including submission openings starting December 28, 2024, and a close date of January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This initiative encourages investigators to engage in translational activities and small clinical studies, focusing on the implementation of clinical prototype devices, non-clinical safety and efficacy testing, and obtaining necessary regulatory approvals for clinical trials. The program emphasizes a milestone-driven approach, requiring collaboration with NIH staff throughout the project, and aims to address health disparities in neurological health. Interested applicants, including various educational and community organizations, must submit their proposals by January 28, 2027, and can find additional information and application guidelines at NIH Grants.
    Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders through a phased grant mechanism (R61/R33). This funding opportunity aims to enhance the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and improve clinical care decisions. The initiative emphasizes the importance of multidisciplinary collaboration and requires applicants to validate biomarkers in a phased approach, with the R61 phase focusing on proof of concept studies and the R33 phase on preliminary clinical validation. Interested applicants should note that the application deadline is January 7, 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-024.html.
    Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Preclinical Models of NeuroHIV in the cART Era" (Funding Opportunity Number: RFA-NS-24-035) aimed at developing innovative small animal models and human cellular systems that accurately reflect the interactions between the central nervous system (CNS) and the immune system in individuals living with HIV. This initiative seeks applications that propose the development and early-stage validation of next-generation humanized models to address cognitive and neurological impairments associated with chronic HIV infection, particularly in the context of antiretroviral therapy (ART). The total funding available for this initiative is approximately $6 million, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the R21 Exploratory/Developmental Research Grant (PAR-21-167) to support innovative research aimed at developing animal models and related biological materials for biomedical studies. This funding opportunity encourages projects that enhance understanding of human health and diseases by creating models that evaluate multiple body systems or diseases affecting them, rather than focusing on a single disease or NIH Institute. With a funding ceiling of $200,000 available for direct costs over a maximum project duration of two years, eligible applicants include higher education institutions, non-profits, and various governmental organizations. The application deadline is January 7, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.